Frequency of hereditary transthyretin amyloidosis among elderly patients with transthyretin cardiomyopathy

Transthyretin amyloid cardiomyopathy (ATTR‐CM) is increasingly recognized as a cause of heart failure in the elderly. Although wild‐type transthyretin amyloidosis is the most frequent form of ATTR‐CM found in the elderly, hereditary transthyretin amyloidosis (ATTRv) can also occur. We sought to determine the prevalence of ATTRv among elderly ATTR‐CM patients, identify predictors of ATTRv and evaluate the clinical consequences of positive genetic testing in this population.

[1]  A. Einstein,et al.  False Positive 99mTc-Pyrophosphate Scanning Leading to Inappropriate Tafamidis Prescriptions. , 2021, JACC. Cardiovascular imaging.

[2]  U. Eriksson,et al.  Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases , 2021, European journal of heart failure.

[3]  P. Elliott,et al.  Efficacy of Tafamidis in Patients With Hereditary and Wild-Type Transthyretin Amyloid Cardiomyopathy: Further Analyses From ATTR-ACT. , 2020, JACC. Heart failure.

[4]  A. Einstein,et al.  Diagnosing Transthyretin Cardiac Amyloidosis by Technetium 99m Pyrophosphate: A Test in Evolution. , 2020, JACC. Cardiovascular imaging.

[5]  Adam Castaño,et al.  Transthyretin amyloid cardiomyopathy in women: frequency, characteristics, and diagnostic challenges , 2020, Heart Failure Reviews.

[6]  F. Domínguez,et al.  Clinical profile and outcome of cardiac amyloidosis in a Spanish referral center. , 2020, Revista espanola de cardiologia.

[7]  A. Petrie,et al.  Natural History, Quality of Life, and Outcome in Cardiac Transthyretin Amyloidosis. , 2019, Circulation.

[8]  Sanjiv J. Shah,et al.  Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy , 2018, The New England journal of medicine.

[9]  M. Leon,et al.  Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement , 2017, European heart journal.

[10]  Sanjiv J. Shah,et al.  Genotype and Phenotype of Transthyretin Cardiac Amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey). , 2016, Journal of the American College of Cardiology.

[11]  S. Frusconi,et al.  The Val142Ile transthyretin cardiac amyloidosis: not only an Afro-American pathogenic variant? A single-centre Italian experience , 2016, Journal of cardiovascular medicine.

[12]  E. González-López,et al.  Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. , 2015, European heart journal.

[13]  E. Boerwinkle,et al.  The amyloidogenic V122I transthyretin variant in elderly black Americans. , 2015, The New England journal of medicine.